A detailed history of Gibbs Wealth Management transactions in Vertex Pharmaceuticals Inc stock. As of the latest transaction made, Gibbs Wealth Management holds 1,216 shares of VRTX stock, worth $527,768. This represents 0.11% of its overall portfolio holdings.

Number of Shares
1,216
Previous 1,433 15.14%
Holding current value
$527,768
Previous $638 Million 25.35%
% of portfolio
0.11%
Previous 0.12%

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2025

Oct 30, 2025

SELL
$366.54 - $479.53 $79,539 - $104,058
-217 Reduced 15.14%
1,216 $476 Million
Q2 2025

Aug 13, 2025

BUY
$421.16 - $509.5 $603,522 - $730,113
1,433 New
1,433 $638 Million
Q1 2025

Nov 04, 2025

BUY
$402.49 - $513.76 $165,825 - $211,669
412 Added 70.31%
998 $484 Million
Q4 2024

Nov 04, 2025

SELL
$396.64 - $516.74 $249,883 - $325,546
-630 Reduced 51.81%
586 $236 Million

Others Institutions Holding VRTX

About VERTEX PHARMACEUTICALS INC


  • Ticker VRTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 256,691,008
  • Market Cap $111B
  • Description
  • Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...
More about VRTX
Track This Portfolio

Track Gibbs Wealth Management Portfolio

Follow Gibbs Wealth Management and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Gibbs Wealth Management, based on Form 13F filings with the SEC.

News

Stay updated on Gibbs Wealth Management with notifications on news.